{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:37:10Z","timestamp":1760834230895,"version":"build-2065373602"},"reference-count":38,"publisher":"BMJ","issue":"2","funder":[{"name":"the Fundamental Research Funds for the Central public welfare research institutes"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,11,30]]},"published-print":{"date-parts":[[2018,2]]},"abstract":"\n Introduction<\/jats:title>\n Coronary artery disease (CAD) not amenable to revascularisation indicates that the coronary arteries have severe diffuse lesions or calcifications, or that CAD is complicated with severe multiple-organ disease. Currently, Western medicines available for the treatment of CAD not amenable to revascularisation are limited. Shexiang Baoxin Pill (SBP), a type of Chinese patent medicine, has been widely used to treat CAD in China for many years. Previous studies have shown that long-term administration of SBP (1\u20132 pills three times daily, for at least 6 months) for treatment of CAD is effective and safe, with a significant, long-term effect. This study aims to evaluate the efficacy and safety of SBP in patients with CAD not amenable to revascularisation.<\/jats:p>\n <\/jats:sec>\n \n Methods and analysis<\/jats:title>\n This is a multicentre, randomised, double-blinded, placebo-controlled clinical trial. A total of 440 participants will be randomly allocated to two groups: the intervention group and the placebo group. Based on conventional treatment with Western medicine, the intervention group will be treated with SBP and the placebo group will be treated with SBP placebo. The primary outcomes include major adverse cardiovascular events (including angina, acute myocardial infarction, pulmonary embolism and aortic dissection). The secondary outcomes include C reactive protein, B-type natriuretic peptide, ECG, echocardiographic parameters (ejection fraction percentage and the E\/A ratio) and hospital readmission rates due to CAD. Assessments will be performed at baseline (before randomisation) and at 24 weeks after randomisation.<\/jats:p>\n <\/jats:sec>\n \n Ethics and dissemination<\/jats:title>\n The protocol has been approved by the Research Ethics Committee of Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences in Beijing, China (reference: 2016-129-KY-01). The results of this study will be published in a peer-reviewed journal and will be used as a basis for a multisite trial.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n NCT03072121<\/jats:ext-link>; Pre-results.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2017-018052","type":"journal-article","created":{"date-parts":[[2018,2,14]],"date-time":"2018-02-14T08:45:16Z","timestamp":1518597916000},"page":"e018052","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of the Shexiang Baoxin Pill for the treatment of coronary artery disease not amenable to revascularisation: study protocol for a randomised, placebo-controlled, double-blinded trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03072121","registry":"10.18810\/clinical-trials-gov","type":"preResults"}],"author":[{"given":"Pan-pan","family":"Tian","sequence":"first","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"},{"name":"Graduate School Department, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Gao","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"},{"name":"Graduate School Department, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Guang\u2019anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China"},{"name":"Graduate School Department, Beijing University of Chinese Medicine, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"2025101811392665000_8.2.e018052.1","first-page":"385","article-title":"Why dentists need to learn the epidemiological status and prevention strategy of coronary heart disease in China","volume":"51","author":"Zhao","year":"2016","journal-title":"Chin J Stomatol"},{"key":"2025101811392665000_8.2.e018052.2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2706"},{"key":"2025101811392665000_8.2.e018052.3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/MCA.0b013e32833bdf53","article-title":"Distribution of left ventricular ejection fraction in angina patients with severe coronary artery disease not amenable to revascularization","volume":"21","author":"Gupta","year":"2010","journal-title":"Coron Artery Dis"},{"key":"2025101811392665000_8.2.e018052.4","first-page":"3363","article-title":"The research progress of treatment methods for coronary heart disease","volume":"17","author":"Luo","year":"2013","journal-title":"Pub Med Forum Mag"},{"key":"2025101811392665000_8.2.e018052.5","first-page":"13","article-title":"Meta-analysis on curative effect and safety of Shexiang Baoxin Wan in treatment of coronary heart diseaseChinese","volume":"4","author":"Zhang","year":"2012","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"2025101811392665000_8.2.e018052.6","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3892\/etm.2014.1630","article-title":"Optimal treatment of multivessel complex coronary artery disease","volume":"7","author":"Sun","year":"2014","journal-title":"Exp Ther Med"},{"key":"2025101811392665000_8.2.e018052.7","first-page":"881","article-title":"Patients with coronary artery disease not amenable to traditional revascularization: Prevalence and 3-year mortality","volume":"119","author":"Williams","year":"2010","journal-title":"Catheter Cardiovasc Interv"},{"key":"2025101811392665000_8.2.e018052.8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.recesp.2015.02.013","article-title":"Diffuse Coronary Artery Disease Not Amenable to Revascularization: Long-term Prognosis","volume":"68","author":"Lozano","year":"2015","journal-title":"Rev Esp Cardiol"},{"key":"2025101811392665000_8.2.e018052.9","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/710750"},{"key":"2025101811392665000_8.2.e018052.10","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3736\/jcim20120604","article-title":"Clinical epidemiology survey of the traditional Chinese medicine etiology and syndrome differentiation of coronary artery disease: study protocol of a multicenter trial","volume":"10","author":"Bi","year":"2012","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"2025101811392665000_8.2.e018052.11","first-page":"114","article-title":"Research on mechanism of Shexiang Baoxin Pill in the treatment of coronary heart disease","volume":"20","author":"Wy","year":"2011","journal-title":"J Emerg Trad Chin Med"},{"key":"2025101811392665000_8.2.e018052.12","first-page":"1409","article-title":"Research progress of Shexiang Baoxin Pill","volume":"47","author":"Liu","year":"2016","journal-title":"Chin Trad Herb Drugs"},{"key":"2025101811392665000_8.2.e018052.13","first-page":"1432","article-title":"[Effect of Shexiang Baoxin pill on coronary vasodilation by analysis of coronary angiography]","volume":"34","author":"Zhang","year":"2014","journal-title":"Zhongguo Zhong Xi Yi Jie He Za Zhi"},{"key":"2025101811392665000_8.2.e018052.14","first-page":"262","article-title":"Mechanism research of Shexiang Baoxin pill on treating coronary artery disease","volume":"31","author":"Zl","year":"2011","journal-title":"Jilin J Trad Chin Med"},{"key":"2025101811392665000_8.2.e018052.15","first-page":"1409","article-title":"Advance in Modern Studies on Shexiang Baoxin Pill","volume":"47","author":"Liu","year":"2016","journal-title":"China Tradit Herb Drugs"},{"key":"2025101811392665000_8.2.e018052.16","first-page":"474","article-title":"Evalution on Clinical Effect of Long Term Shexiang Baoxin Pill Administration for Treatment of Coronary Heart Disease","volume":"30","author":"Zhu","year":"2010","journal-title":"Chin J Integr Med"},{"key":"2025101811392665000_8.2.e018052.17","first-page":"1015","article-title":"Curative effect observation of Shexiang Baoxin Pill on multi-vessel lesions in CAD without revascularization","volume":"13","author":"Jw","year":"2015","journal-title":"Chin J Integr Med"},{"key":"2025101811392665000_8.2.e018052.18","first-page":"184","article-title":"Long-term effect analysis of long term Shexiang Baoxin Pill administration for treatment of coronary heart disease","volume":"14","author":"Yq","year":"2016","journal-title":"Guid Chin Med"},{"key":"2025101811392665000_8.2.e018052.19","first-page":"2027","article-title":"Observation on adverse reaction and safety of long term shexiang baoxin pill administration in patients with coronary heart disease","volume":"32","author":"Zhu","year":"2010","journal-title":"Chin Trad Pat Med"},{"key":"2025101811392665000_8.2.e018052.20","first-page":"163","article-title":"Discussion on Adverse Reaction and Safety of Long Term Shexiang Baoxin Pill Administration in Patients with Coronary Heart Disease","volume":"4","author":"Zhang","year":"2016","journal-title":"Chin J Integr Tradit West Med Cardiovasc Dis"},{"key":"2025101811392665000_8.2.e018052.21","first-page":"195","article-title":"Editor committee of Chinese journal of cardiology. Chinese guidelines for the prevention and management of chronic stable angina","volume":"35","author":"Cardiology Branch of Chinese Medical Association","year":"2007","journal-title":"Chin J Cardio"},{"key":"2025101811392665000_8.2.e018052.22","first-page":"353","article-title":"Editor committee of Chinese journal of cardiology. Guidelines for the diagnosis and management of non-ST-segment elevation myocardial infarction Acute Coronary Syndromes","volume":"40","author":"Cardiology Branch of Chinese Medical Association","year":"2012","journal-title":"Chin J Cardio"},{"key":"2025101811392665000_8.2.e018052.23","first-page":"675","article-title":"Editor committee of Chinese journal of cardiology. Guidelines for the diagnosis and management of acute ST-segment elevation myocardial infarction","volume":"38","author":"Cardiology Branch of Chinese Medical Association","year":"2010","journal-title":"Chin J Cardio"},{"key":"2025101811392665000_8.2.e018052.24","unstructured":"Zheng XY . Guideline of clinical research of new drugs of traditional Chinese medicine: chest obstruction. Chin Med Sci & Tech Press 2002:68\u201373."},{"key":"2025101811392665000_8.2.e018052.25","first-page":"105","article-title":"Heart of musk pill combined western medicine therapy of coronary heart disease unstable angina random parallel control study","volume":"28","author":"Xie","year":"2014","journal-title":"Chin J Pract Int Med"},{"key":"2025101811392665000_8.2.e018052.26","unstructured":"Ly G , Sun ZX . Progress of studies on aspirin resistance and clopidogrel resistance. Chin Hosp Pharm J 2016:866\u20139."},{"key":"2025101811392665000_8.2.e018052.27","first-page":"38","article-title":"Determinants of the medication adherence behavior among elderly patients with coronary heart diseases","volume":"5","author":"Ma H J","year":"2015","journal-title":"J Nurs Educ Pract"},{"key":"2025101811392665000_8.2.e018052.28","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/nrcardio.2014.177-c1","article-title":"Integrating traditional Chinese medicine into Western cardiovascular medicine: an evidence-based approach","volume":"12","author":"Xiong","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"2025101811392665000_8.2.e018052.29","doi-asserted-by":"publisher","DOI":"10.2174\/1570161112666141014153735"},{"key":"2025101811392665000_8.2.e018052.30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/809741","article-title":"Herbal medicines for cardiovascular diseases","volume":"2014","author":"Xiong","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"2025101811392665000_8.2.e018052.31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2014\/107501","article-title":"Protective effect of tetramethylpyrazine on myocardial ischemia-reperfusion injury","volume":"2014","author":"Qian","year":"2014","journal-title":"Evid Based Complement Alternat Med"},{"key":"2025101811392665000_8.2.e018052.32","unstructured":"Zhang H , Zhu HY . New interpretation of the advantages of traditional Chinese medicine in the treatment of cardiovascular disease. Chin Arch Tradit Chin Med 2001(03):214\u201322."},{"key":"2025101811392665000_8.2.e018052.33","unstructured":"Liu HX , Liu P . Clinical characteristic advantage of traditional Chinese medicine in prevention and treatment of cardiovascular disease. Beijing J Tradit Chin Med 2007(07):396\u20139."},{"key":"2025101811392665000_8.2.e018052.34","article-title":"Current situation and re-understanding of syndrome and formula syndrome in Chinese medicine","volume":"02","author":"Wang","year":"2012","journal-title":"Internal Medicine: Open Access"},{"key":"2025101811392665000_8.2.e018052.35","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/710750"},{"key":"2025101811392665000_8.2.e018052.36","unstructured":"YL X , WX D . Research summary and consideration of Chinese medicine for the treatment of coronary disease. Heart disease branch of China association of Chinese medicine annual meeting and Beijing Chinese medicine academic society of professional committee on cardiovascular disease 2012:143\u20135."},{"key":"2025101811392665000_8.2.e018052.37","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025101811392665000_8.2.e018052.38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/M17-1067","article-title":"Randomized Trials of Chinese Herbal Medicine: A New Extension of the CONSORT Statement","volume":"167","author":"Linde","year":"2017","journal-title":"Ann Intern Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-018052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:39:36Z","timestamp":1760812776000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-018052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,2,14]]},"published-print":{"date-parts":[[2018,2]]}},"alternative-id":["10.1136\/bmjopen-2017-018052"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-018052","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2018,2]]}}}